natgillin/translations-raw huggingface dataset:
Disse studier, der omfattede 1308 patienter, som i gennemsnit havde haft fokale anfald i 23 år, blev designet til at vurdere lacosamids sikkerhed og virkning, når det blev givet samtidig med 1-3 antiepileptiske lægemidler til patienter med ukontrollerede fokale anfald med eller uden sekundær generalisering. 
These trials, involving 1,308 patients with a history of an average of 23 years of partial-onset seizures, were designed to evaluate the efficacy and safety of lacosamide when administered concomitantly with 1-3 antiepileptic medicinal products in patients with uncontrolled partial-onset seizures with or without secondary generalisation.
14 filmovertrukne tabletter 56 filmovertrukne tabletter 60 filmovertrukne tabletter 168 filmovertrukne tabletter 14 x 1 filmovertrukket tablet 56 x 1 filmovertrukket tablet 
14 film-coated tablets 56 film-coated tablets 60 film-coated tablets 168 film-coated tablets 14 x 1 film-coated tablet 56 x 1 film-coated tablet
Effekten af lacosamid som tillægsbehandling ved de anbefalede doser (200 mg daglig, 400 mg daglig) blev dokumenteret i 3 randomiserede, placebo-kontrollerede, multicenter-kliniske studier med en vedligeholdelsesperiode på 12 uger. 
The efficacy of lacosamide as adjunctive therapy at recommended doses (200 mg/day, 400 mg/day) was established in 3 multicenter, randomized, placebo-controlled clinical trials with a 12-week maintenance period.
• Hvis De har glemt at tage en dosis mere end de første 6 timer efter den planlagte dosis, må De ikke længere tage den glemte tablet. 
• If you have missed a dose beyond the first 6 hours of the scheduled dose, do not take the missed tablet anymore.
Tilfælde af AV-blok af anden eller tredje grad i forbindelse med lacosamidbehandling er imidlertid blevet rapporteret efter markedsføring. 
However, cases with second and third-degree AV Block associated with lacosamide treatment have been reported in postmarketing experience.
Behandlingsstartpakning (kun til unge og børn, der vejer 50 kg eller derover og til voksne) Lacosamide Accord 50 mg filmovertrukne tabletter 
Treatment initiation pack (in adolescent and children weighing 50 kg or more and adults only) Lacosamide Accord 50 mg film-coated tablets
Behandling med lacosamid kan også indledes med en enkelt støddosis på 200 mg, efterfulgt af vedligeholdelsesbehandling med 100 mg to gange daglig (200 mg/dag) ca. 12 timer senere. 
Lacosamide treatment may also be initiated with a single loading dose of 200 mg, followed approximately 12 hours later by a 100 mg twice a day (200 mg/day) maintenance dose regimen.
I alle disse kontrollerede studier var seponeringsraten på grund af bivirkninger 12,2 % for patienter randomiseret til lacosamid, og 1,6 % for patienter randomiseret til placebo. 
In all of these controlled studies, the discontinuation rate due to adverse reactions was 12.2 % for patients randomized to lacosamide and 1.6 % for patients randomized to placebo.
Symptomer Symptomer observeret efter en tilsigtet eller utilsigtet overdosis med lacosamid er hovedsageligt forbundet med centralnervesystemet eller mave-tarm-kanalen. 
Symptoms observed after an accidental or intentional overdose of lacosamide are primarily associated with CNS and gastrointestinal system.
• De har et hjerteproblem, der påvirker hjerterytmen, og De ofte har en særlig langsom, hurtig eller uregelmæssig puls (som f.eks. AV-blok, atrieflimren og atrieflagen). 
• you have a heart problem that affects the beat of your heart and you often have a particulary slow, fast or irregular heart beat (such as AV block, atrial fibrillation and atrial flutter).
• Medicin, der anvendes til behandling af bakterieinfektioner kaldet clarithromycin eller rifampicin; 
• medicines used to treat bacterial infections called clarithromycin or rifampicin;
WESSLING Hungary Kft, Anonymus u. 6., Budapest, 1045, Ungarn 
WESSLING Hungary Kft, Anonymus u. 6., Budapest, 1045, Hungary
Den hyppigst forekommende hjerterelaterede bivirkning, som blev rapporteret hos den ældre population sammenlignet med den yngre voksenpopulation, var første grads AV-blok. 
The most frequent cardiac-related adverse reaction reported in elderly compared to the younger adult population was first-degree AV block.
50 mg: Hver filmovertrukket tablet indeholder 0,105 mg lecithin (soja) 100 mg: Hver filmovertrukket tablet indeholder 0,210 mg lecithin (soja) 150 mg: Hver filmovertrukket tablet indeholder 0,315 mg lecithin (soja) 200 mg: Hver filmovertrukket tablet indeholder 0,420 mg lecithin (soja) 
50 mg: Each film-coated tablet contains 0.105 mg of lecithin (soya) 100 mg: Each film-coated tablet contains 0.210 mg of lecithin (soya) 150 mg: Each film-coated tablet contains 0.315 mg of lecithin (soya) 200 mg: Each film-coated tablet contains 0.420 mg of lecithin (soya) For the full list of excipients, see section 6.1.
• Blodprøver kan vise unormal leverfunktion, leverskade 
Blood tests may show abnormal liver function , liver injury;
Yderkarton 
Outer carton
Lacosamid bør anvendes med forsigtighed hos patienter i behandling med lægemidler, som man ved, er forbundet med PR-forlængelse (herunder natriumkanalblokerende antiepileptika) samt hos patienter i behandling med antiarytmetika. 
Lacosamide should be used with caution in patients treated with medicinal products known to be associated with PR prolongation (including sodium channel blocking antiepileptic medicinal products) and in patients treated with antiarrhythmics.
Lacosamid 600 mg viste sig også at være effektiv i kontrollerede studier med tillægsbehandling, selvom effekten var den samme som ved 400 mg/dag og patienterne ofte tålte denne dosis dårligere på grund af bivirkninger relateret til centralnervesystemet og mavetarm-kanalen. 
Lacosamide 600 mg/day was also shown to be effective in controlled adjunctive therapy trials, although the efficacy was similar to 400 mg/day and patients were less likely to tolerate this dose because of CNS- and gastrointestinal-related adverse reactions.
Afhængigt af respons og tolerabilitet kan Lacosamide Accord 150 mg-tabletter tages to gange daglig i tredje uge og Lacosamide Accord 200 mg-tabletter to gange daglig i fjerde uge. 
Depending on response and tolerability, Lacosamide Accord 150 mg tablets may be taken twice a day during the third week and Lacosamide Accord 200 mg tablets twice a day during the fourth week.
WESSLING Hungary Kft, Anonymus u. 6., Budapest, 1045, Ungarn eller 
WESSLING Hungary Kft, Anonymus u. 6., Budapest, 1045, Hungary or
De starter behandlingen med en lav dosis Lacosamide Accord, almindeligvis 50 mg 2 gange dagligt, og dosis øges uge efter uge. 
You will start your treatment with a low dose of Lacosamide Accord, usually 50 mg twice a day, and increase it week by week.
De mest almindeligt rapporterede bivirkninger (≥10 %) ved lacosamidbehandling var svimmelhed, hovedpine, kvalme og diplopi (dobbeltsyn). 
The most frequently reported adverse reactions (≥10 %) with lacosamide treatment were dizziness, headache, nausea and diplopia.
• Ondt i halsen (pharyngitis); 
• Sore throat (pharyngitis);
Unge og børn der vejer 50 kg eller derover og voksne Hvis De kun tager Lacosamide Accord mod epilepsi Den sædvanlige startdosis af Lacosamide Accord er 50 mg to gange dagligt. 
Adolescents and children weighing 50 kg or more and adults only When you take Lacosamide Accord on its own The usual starting dose of Lacosamide Accord is 50 mg twice a day.
• Hurtige og ukontrollerbare øjenbevægelser (nystagmus), sløret syn 
Rapid and uncontrollable movements of the eyes (nystagmus), blurred vision; A spinning sensation (vertigo), feeling drunk;
Johnsons syndrom(1) Toksisk epidermal nekrolyse(1) 
Stevens-Johnson syndrome(1) Toxic epidermal necrolysis(1)
Patienterne blev randomiseret i forholdet 1:1 til enten carbamazepin CR eller lacosamid, givet som tabletter. 
The patients were randomized to carbamazepine CR or lacosamide, provided as tablets, in a 1:1 ratio.
Mikrokrystallinsk cellulose Hydroxypropylcellulose-L Hydroxypropylcellulose (lavsubstitueret) Silica, kolloid, vandfri Crospovidon 
Microcrystalline cellulose Hydroxy propyl cellulose-L Hydroxy propyl cellulose (low substituted) Silica, colloidal, anhydrous Crospovidone
Samlet var omfanget af personer med en 50 % reduktion i hyppigheden af anfald 23 %, 34 % og 40 % for placebo, lacosamid 200 mg/dag og lacosamid 400 mg/dag. 
Overall the proportion of subjects with a 50% reduction in seizure frequency was 23 %, 34 %, and 40 % for placebo, lacosamide 200 mg/day and lacosamide 400 mg/day.
Hvis en dosis glemmes, skal patienten instrueres i at tage den glemte dosis med det samme og derefter tage den næste dosis lacosamid til det normale tidspunkt. 
If a dose is missed, the patient should be instructed to take the missed dose immediately, and then to take the next dose of lacosamide at the regularly scheduled time.
Hos unghunde begyndte forbigående og dosisrelaterede CNSkliniske tegn at blive observeret ved systemiske eksponeringsniveauer under den forventede kliniske eksponering. 
In juvenile dogs, transient and dose-related CNS clinical signs started to be observed at systemic exposure levels below the expected clinical exposure.
Egnede patienter på et stabilt dosisregimen på 1 til 3 antiepileptiske lægemidler, som stadig oplevede mindst 2 partielle anfald i løbet af de 4 uger, der gik forud for screening, med anfaldsfri fase på ikke mere end 21 dage i 8 ugers perioden før starten på baseline perioden, blev randomiseret til at få enten placebo (n=172) eller lacosamid (n=171). 
Eligible patients on a stable dose regimen of 1 to ≤ 3 antiepileptic medicinal products, who still experienced at least 2 partial-onset seizures during the 4 weeks prior to screening with seizure-free phase no longer than 21 days in the 8-week period prior to entry into the baseline period, were randomised to receive either placebo (n=172) or lacosamide (n=171).
08040 Barcelona, Spanien eller 
08039 Barcelona, Spain
I dette studie blev 425 patienter mellem 16 og 70 år med ukontrollerede anfald af partiel type, som tog stabile doser af 1 eller 2 markedsførte antiepileptiske lægemidler, randomiseret til konvertering til lacosamid-monoterapi (enten 400 mg/dag eller 300 mg/dag, i forholdet 3:1). 
In this study, 425 patients aged 16 to 70 years with uncontrolled partial-onset seizures taking stable doses of 1 or 2 marketed antiepileptic medicinal products were randomized to be converted to lacosamide monotherapy (either 400mg/day or 300mg/day in a 3:1 ratio).
Lacosamide Accord er indiceret som monoterapi og tillægsbehandling af fokale anfald med eller uden sekundær generalisering hos voksne, unge og børn fra 4 år med epilepsi. 
Lacosamide Accord is indicated as monotherapy and adjunctive therapy in the treatment of partialonset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
Sikkerhedsprofilen af lacosamid i placebo-kontrollerede (se oplysninger om studiet i punkt 5.1) og i open-label studier (n=408) som tillægsbehandling hos børn fra 4 år var i overensstemmelse med sikkerhedsprofilen observeret hos voksne, selv om hyppigheden af nogle bivirkninger (somnolens, opkastning og kramper) var øget, og der er rapporteret yderligere bivirkninger (nasopharyngitis, pyreksi, pharyngitis, nedsat appetit, letargi og unormal adfærd) hos pædiatriske patienter: nasopharyngitis (15,7 %), opkastning (14,7 %), somnolens (14,0 %), svimmelhed (13,5 %), pyreksi (13,0 %), kramper (7,8 %), nedsat appetit (5,9 %), pharyngitis (4,7 %), letargi (2,7 %) og unormal adfærd (1,7 %).I alt rapporterede 67,8 % af patienter, randomiseret til lacosamid, og 58,1 % af patienter, randomiseret til placebo, mindst 1 bivirkning. 
The safety profile of lacosamide in placebo-controlled (see study details in section 5.1) and in openlabel studies (n=408) in adjunctive therapy in children from 4 years of age was consistent with the safety profile observed in adults although the frequency of some adverse reactions (somnolence, vomiting and convulsion) was increased and additional adverse reactions (nasopharyngitis, pyrexia, pharyngitis, decreased appetite, lethargy and abnormal behaviour) have been reported in paediatric patients: nasopharyngitis (15.7 %), vomiting (14.7 %), somnolence (14.0 %), dizziness (13.5 %), pyrexia (13.0 %), convulsion (7.8 %), decreased appetite (5.9 %), pharyngitis (4.7 %), lethargy (2.7 %) and abnormal behaviour (1.7 %).
Titandioxid (E171) Lecithin (soja) 
Titanium dioxide (E171) Lecithin (soya)
Bivirkninger fra nervesystemet, såsom svimmelhed, kan være hyppigere efter en enkelt støddosis. 
Nervous system side effects such as dizziness may be higher after a single “loading” dose.
Dette vil være indtil De når en vedligeholdelsesdosis mellem 100 mg og 300 mg to gange dagligt. 
This will be until you reach a maintenance dose between 100 mg and 300 mg twice a day.
• Lacosamid Accord bruges til unge og børn i alderen 4 år og ældre, der vejer 50 kg eller derover og til voksne. 
• Lacosamide Accord is used in adolescents and children aged 4 years and older weighing 50 kg or more and in adults.
Den sædvanlige startdosis af Lacosamide Accord er 50 mg to gange dagligt. 
The usual starting dose of Lacosamide Accord is 50 mg twice a day.
100 mg/dag eller 200 mg/dag 100 mg/dag 
100 mg/day or 200 mg/day
Det skal De vide, før De begynder at tage Lacosamide Accord 
What you need to know before you take Lacosamide Accord
Tabletkerne: Mikrokrystallinsk cellulose, hydroxypropylcellulose-L, hydroxypropylcellulose (lavsubstitueret), kolloid vandfri silica, crospovidon og magnesiumstearat. 
Tablet core: Microcrystalline cellulose, hydroxy propyl cellulose-L, hydroxy propyl cellulose (low substituted), silica colloidal anhydrous, crospovidone and magnesium stearate.
Lacosamide Accord indeholder lacosamid. 
Lacosamide Accord contains lacosamide.
De administrerede doser af lacosamid varierede fra 2 til 17,8 mg/kg /dag med indtag to gange dagligt, af højst 600 mg/dag for børn, der vejede 50 kg eller derover. 
The administered lacosamide doses ranged from 2 to 17.8 mg/kg/day in twice daily intake, with a maximum of 600 mg/day for children weighing 50 kg or more.
Baseret på analysen af puljede placebo-kontrollerede kliniske studier med tillægsbehandling, omfattende 1.308 patienter med fokale anfald, fandt man, at i alt 61,9 % af patienterne, der blev randomiseret til behandling med lacosamid, og 35,2 % af patienterne, der blev randomiseret til behandling med placebo, rapporterede mindst 1 bivirkning. 
Based on the analysis of pooled placebo-controlled clinical trials in adjunctive therapy in 1,308 patients with partial-onset seizures, a total of 61.9 % of patients randomized to lacosamide and 35.2 % of patients randomized to placebo reported at least 1 adverse reaction.
Det vides heller ikke, om Lacosamide Accord går over i modermælken. 
Also, it is not known whether Lacosamide Accord passes into the breast milk.
Overfølsomhed over for det aktive stof, sojalecitin eller over for et eller flere af hjælpestofferne anført i pkt. 
Hypersensitivity to the active substance, soya lecithin or to any of the excipients listed in section 6.1.
Polyethylenglycol talkum 
Polyethylene glycol Talc
Behandlingsinitieringspakken er kun egnet til unge og børn, der vejer 50 kg eller derover og til voksne. 
The treatment initiation pack is only suitable in adolescents and children weighing 50 kg or more and in adults.
Dette vil være indtil De når en vedligeholdelsesdosis mellem 100 mg og 200 mg to gange dagligt. 
This will be until you reach a maintenance dose between 100 mg and 200 mg twice a day.
Hvis De tager Lacosamide Accord, og De oplever symptomer på unormal puls (såsom langsom, hurtig eller uregelmæssig puls, hjertebanken, åndenød, følelse af at være uklar, være ved at besvime), skal De straks søge læge (se pkt. 
If you are taking Lacosamide Accord and you are experiencing symptoms of abnormal heartbeat (such as slow, rapid or irregular heartbeat, palpitations, shortness of breath, feeling lightheaded, fainting), seek medical advice immediately (see section 4).
Lægen kan også ordinere en startdosis på 100 mg Lacosamide Accord to gange dagligt. 
Your doctor may also prescribe a starting dose of 100 mg of Lacosamide Accord twice a day.
• En urtemedicin, der anvendes til behandling af mild angst og depression kaldet perikum. 
• a herbal medicine used to treat mild anxiety and depression called St.John's wort.
Lacosamide Accord er indiceret som monoterapi og tillægsbehandling af fokale anfald med eller uden sekundær generalisering hos unge og børn fra 4 år, der vejer 50 kg eller derover og hos voksne med epilepsi. 
Lacosamide Accord is indicated as monotherapy and adjunctive therapy in the treatment of partialonset seizures with or without secondary generalisation in adolescents and children from 4 years of age weighing 50 kg or more and in adults with epilepsy.
Baseret på en analyse af data fra et non-inferioritetsstudie med monoterapi, som sammenlignede lacosamid med carbamazepin depotformulering (CR), var de hyppigst rapporterede bivirkninger (≥10 %) for lacosamid, hovedpine og svimmelhed. 
Based on the analysis of data from a non-inferiority monotherapy clinical trial comparing lacosamide to carbamazepine controlled release (CR), the most frequently reported adverse reactions (≥ 10 %) for lacosamide were headache and dizziness.
Dosistilskud efter hæmodialyse anbefales derfor (se pkt. 
Therefore dosage supplementation following haemodialysis is recommended (see section 4.2).
• Sygdomsfornemmelse (kvalme) eller sygdom (opkastning); 
• feeling sick (nausea) or being sick (vomiting);
• Unormale tanker eller manglende virkelighedsopfattelse 
Abnormal thinking or losing touch with reality;
Tabletovertræk Polyvinylalkohol Polyethylenglycol Talkum 
Polyvinyl alcohol Polyethylene glycol Talc
ALATstigning til ≥ 3 x øvre normalgrænse forekom hos 0,7 % (7/935) af lacosamid-patienterne og hos 0 % (0/356) af placebopatienterne. 
Elevations of ALT to ≥3x ULN occurred in 0.7 % (7/935) of Lacosamide patients and 0 % (0/356) of placebo patients.
Unge og børn, der vejer 50 kg eller derover, samt voksne Hvis De kun tager Lacosamide Accord 
Adolescents and children weighing 50 kg or more and adults When you take Lacosamide Accord on its own
In vitro-data viser, at CYP2C9, CYP2C19 og CYP3A4 kan katalysere dannelsen af O-desmethylmetabolitten. 
In vitro data show that CYP2C9, CYP2C19 and CYP3A4 are capable of catalysing the formation of the Odesmethyl metabolite.
Hvis De har glemt at tage Lacosamide Accord 
If you forget to take Lacosamide Accord
• Opkastning, tør mund, forstoppelse, fordøjelsesbesvær, for megen luft i mave eller tarm, diarré 
Being sick (vomiting), dry mouth, constipation, indigestion, excessive gas in the stomach or bowel, diarrhoea;
Den anden uge tager patienten Lacosamide Accord 100 mg-tabletter to gange daglig. 
During the second week, the patient takes Lacosamide Accord 100 mg tablets twice a day.
• Udbredt udslæt med blærer og skællende hud, især omkring munden, næsen, øjnene og kønsdelene (Stevens-Johnsons syndrom), og en mere alvorlig form, der forårsager hudafskalning på mere end 30 % af kropsoverfladen (toksisk epidermal nekrolyse); 
Blood tests may show increased levels of liver enzymes and a type of white blood cell (eosinophilia); A widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome), and a more severe form causing skin peeling in more than 30 % of the body surface (toxic epidermal necrolysis);
Den første behandlingsdag starter patienten med Lacosamide Accord 50 mg-tabletter to gange daglig. 
On the first day of treatment the patient starts with Lacosamide Accord 50 mg tablets twice a day.
Lacosamide Accord kan medføre svimmelhed, der vil kunne øge risikoen for tilskadekomst eller fald. 
Lacosamide Accord may make you dizzy -this could increase the risk of accidental injury or a fall.
Pakningen med 14 x 1 eller 56 x 1 fås som perforeret enhedsdosis PVC-PVDC/aluminiumsblister forseglet med en aluminiumsfolie. 
The 14 x 1 or 56 x 1 tablet pack is available as perforated unit dose PVC-PVDC/Aluminium blisters sealed with an aluminium foil, all other packs are available with standard PVC-PVDC/Aluminium blisters sealed with an aluminium foil.
Til unge og voksne, der vejer 50 kg eller derover kan en støddosis på 200 mg overvejes, dog bør yderligere dosistitrering (>200 mg/dag) ske med forsigtighed. 
In adolescents and adults weighing 50 kg or more, a loading dose of 200 mg may be considered, but further dose titration (> 200 mg daily) should be performed with caution.
Hvis De holder op med at tage Lacosamide Accord 
If you stop taking Lacosamide Accord
Opkastning Forstoppelse Flatulens Dyspepsi Mundtørhed Diarré 
Flatulence Dyspepsia Dry mouth Diarrhoea
Unormale leverfunktionsprøver(2) 
Liver function test abnormal (2)
• Hvis lægen beslutter at stoppe behandlingen med Lacosamide Accord, vil han eller hun fortælle 
• If your doctor decides to stop your treatment with Lacosamide Accord , they will tell you how to decrease the dose step by step.
Pædiatrisk population Unge og børn på 50 kg eller derover 
Paediatric population Adolescents and children weighing 50 kg or more
• Problemer med at holde balancen, rysten (tremor), prikkende og stikkende fornemmelse i huden 
Problems in keeping your balance, shaking (tremor), tingling (paresthesia) or muscle spasms, falling easily and getting bruises;
Hvis De vejer 50 kg hver uge eller mere, kan lægen beslutte at starte behandlingen med Lacosamide Accord med en enkelt ”støddosis” på 200 mg. 
If you weigh 50 kg or more, your doctor may decide to start Lacosamide Accord treatment with a single “loading” dose of 200 mg. You would then start your ongoing maintenance dose 12 hours later.
Hvad Lacosamide Accord er 
What Lacosamide Accord is
• Allergisk reaktion over for lægemidlet, nældefeber 
Allergic reaction to medicine intake, hives;
Den følgende tabel opsummerer den anbefalede dosering ved tillægsbehandling til børn og unge, der vejer mindre end 50 kg. 
The following table summarises the recommended posology in adjunctive therapy for children and adolescents weighing less than 50 kg.
Lacosamide Accord indeholder sojalecithin. 
Lacosamide Accord contains soya lecithin.
Der blev observeret nedsat atrial- og ventrikulær ledningsevne, atrioventrikulær blok og atrioventrikulær dissociation i bedøvede hunde og Cynomolgus-aber ved intravenøse doser på 15-60 mg/kg. 
In anesthetized dogs and Cynomolgus monkeys, at intravenous doses of 15-60 mg/kg, slowing of atrial and ventricular conductivity, atrioventricular block and atrioventricular dissociation were seen.
Hvad Lacosamide Accord bruges til 
What Lacosamide Accord is used for
Hver pakning á 56 filmovertrukne tabletter til en 4 ugers behandlingsplan indeholder: 14 filmovertrukne Lacosamide Accord-tabletter 50 mg 14 filmovertrukne Lacosamide Accord-tabletter 100 mg 14 filmovertrukne Lacosamide Accord-tabletter 150 mg 14 filmovertrukne Lacosamide Accord-tabletter 200 mg 
Each pack of 56 film-coated tablets for a 4-week treatment schedule contains: 14 film-coated tablets of Lacosamide Accord 50 mg 14 film-coated tablets of Lacosamide Accord 100 mg 14 film-coated tablets of Lacosamide Accord 150 mg 14 film-coated tablets of Lacosamide Accord 200 mg
Hos pædiatriske patienter, der vejer 50 kg eller derover og hos voksne patienter med alvorligt nedsat nyrefunktion (CLCR ≤30 ml/min) eller med nyresygdom i slutstadiet anbefales en maksimal dosis på 250 mg/dag og dosistitering bør foretages med forsigtighed. 
In paediatric patients weighing 50 kg or more and in adult patients with severe renal impairment (CLCR ≤30 ml/min) or with end-stage renal disease, a maximum dose of 250 mg/day is recommended and the dose titration should be performed with caution.
Maksimal anbefalet dosis hos patienter ≥ 30 kg til < 50 kg 
Maximum recommended dose in patients ≥ 30 kg to < 50 kg up to 8 mg/kg/day
Hvis De har taget for meget Lacosamide Accord Kontakt straks lægen, hvis De har taget for meget Lacosamide Accord. 
If you take more Lacosamide Accord than you should If you have taken more Lacosamide Accord than you should, contact your doctor immediately.